#immunotherapy

Keytruda showed modest benefits for people with hepatocellular carcinoma, and combining Opdivo with Yervoy improved outcomes.

Seventy percent of liver cancer patients had either a partial response or stable disease.

A third of patients taking neoadjuvant Opdivo had complete responses in an early analysis.

Half of people with worse liver function responded well to immunotherapy.

A second immunotherapy option is now available for hepatocellular carcinoma.

Engineered T cells prevent recurrence over five years.

Immunotherapy had a low response rate, but most responders continue to do well.

The median survival exceeded 15 months for patients previously treated with the only approved first-line therapy.

Opdivo will be used to treat hepatocellular carcinoma, which can be caused by hepatitis B or C.